The role of natalizumab in hematopoietic stem cell mobilization

Expert Opinion on Biological Therapy

Volumn 9, Issue 8, 2009, Pages 1099-1106

  Neumann, Frank ^a   Zohren, Fabian ^a   Haas, Rainer ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Hematopoietic stem cells; Natalizumab; VLA 4

Indexed keywords

ALPHA4 INTEGRIN; ANTIBODY; BETA INTERFERON; CD34 ANTIGEN; CYTOTOXIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MONOCLONAL ANTIBODY; NATALIZUMAB; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4;

ACUTE GRANULOCYTIC LEUKEMIA; ANAPHYLAXIS; CROHN DISEASE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FEVER; FOOD AND DRUG ADMINISTRATION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MULTIPLE SCLEROSIS; MYELODYSPLASTIC SYNDROME; NONHUMAN; OPPORTUNISTIC INFECTION; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN EXPRESSION; RASH; REVIEW; RIGOR; STEM CELL MOBILIZATION; TREATMENT PLANNING; URTICARIA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD34; CLINICAL TRIALS AS TOPIC; HEMATOLOGIC DISEASES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; MODELS, BIOLOGICAL; MULTIPLE SCLEROSIS;

EID: 67650682526     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590903055011     Document Type: Review

References (64)

1. Ransohoff RM. Natalizumab for multiple sclerosis. N Engl J Med 2007;356:2622-2629
2. Rice GP, Hartung HP, Calabresi PA. Anti-αintegrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005;64:1336-1342 (Pubitemid 40570497)
3. Ghosh S. Therapeutic value of alpha-4 integrin blockade in inflammatory bowel disease:the role of natalizumab. Expert Opin Biol Ther 2003;3:995-1000 (Pubitemid 37093154)
4. Verfaillie CM, Hurley R, Bhatia R, et al. Role of bone marrow matrix in normal and abnormal hematopoiesis. Crit Rev Oncol Hematol 1994;16:201-224 (Pubitemid 24210173)
5. Prosper F, Stroncek D, Mccarthy JB, et al. Mobilization and homing of peripheral blood progenitors is related to reversible downregulation of α4β1 integrin expression and function. J Clin Invest 1998;101:2456-2467 (Pubitemid 28270440)
6. Whetton AD, Graham GJ. Homing and mobilization in the stem cell niche. Trends Cell Biol 1999;9:233-238 (Pubitemid 29244135)
7. Miyake K, Weissman IL, Greenberger JS, et al. Evidence for a role of the integrin VLA-4 in lympho-hemopoiesis. J Exp Med 1991;173:599-607
8. Yanai N, Sekine C, Yagita H, et al. Roles for integrin very late activation antigen-4 in stroma-dependent erythropoiesis. Blood 1994;83:2844-2850 (Pubitemid 24142715)
9. Hamamura K, Matsuda H, Takeuchi Y, et al. A critical role of VLA-4 in erythropoiesis in vivo. Blood 1996;87:2513-2517 (Pubitemid 26086897)
10. Soligo D, Schiro R, Luksch R, et al. Expression of integrins in human bone marrow. Br J Haematol 1990;76:323-332 (Pubitemid 20367840)
11. Verfaillie CM, Mccarthy JB, Mcglave PB. Differentiation of primitive human multipotent hematopoietic progenitors into single lineage clonogenic progenitors is accompanied by alteration in their interaction with fibronectin. J Exp Med 1991;174:693-703
12. Simmons PJ, Masinovsky B, Longenecker BM, et al. Vascular cell adhesion molecule-1 expressed by bone marrow stromal cells mediates the binding of hematopoietic progenitor cells. Blood 1992;80:388-395
13. Teixido J, Hemler ME, Greenberger JS, et al. Role of β1 and β2 integrins in the adhesion of human CD34hi stem cells to bone marrow stroma. J Clin Invest 1992;90:358-367
14. Liesveld JL, Winslow JM, Frediani KE, et al. Expression of integrins and examination of their adhesive function in normal and leukemic hematopoietic cells. Blood 1993;81:112-121 (Pubitemid 23013684)
15. Kinashi T, Springer TA. Adhesion molecules in hematopoietic cells. Blood Cells 1994;20:25-44
16. + progenitor cells from bone marrow and peripheral blood during G-CSF-enhanced recovery. Exp Hematol 1995;23:1535-1542
17. Leavesley DI, Oliver JM, Swart BW, et al. Signals from platelet/endothelial cell adhesion molecule enhance the adhesive activity of the very late antigen-4 integrin of human CD34+ hemopoietic progenitor cells. J Immunol 1994;153:4673-4683 (Pubitemid 24346863)
18. + progenitors in G0/G1 versus S+G2/M phases of the cell cycle. Blood 1998;92:842-848
19. Bellucci R, De Propris MS, Buccisano F et al. Modulation of VLA-4 and L-selectin expression on normal CD34+ cells during mobilization with G-CSF. Bone Marrow Transplant 1999;23:1-8 (Pubitemid 29050171)
20. Lichterfeld M, Martin S, Burkly L, et al. Mobilization of CD34+ haematopoietic stem cells is associated with a functional inactivation of the integrin very late antigen 4. Br J Haematol 2000;110:71-81 (Pubitemid 30625595)
21. Papayannopoulou T, Nakamoto B. Peripheralization of hemopoietic progenitors in primates treated with anti-VLA4 integrin. Proc Natl Acad Sci USA 1993;90:9374-9378 This paper presents data demonstrating the mobilizing effect of natalizumab in primates. (Pubitemid 23315786)
22. Craddock CF, Nakamoto B, Andrews RG, et al. Antibodies to VLA4 integrin mobilize long-term repopulating cells and augment cytokine-induced mobilization in primates and mice. Blood 1997;90:4779-4788 (Pubitemid 28007191)
23. Vermeulen M, Lepesteur F, Gagnerault MC, et al. Role of adhesion molecules in the homing and mobilization of murine hematopoietic stem and progenitor cells. Blood 1998;92:894-900 (Pubitemid 28355472)
24. Papayannopoulou T, Priestley GV, Nakamoto B. Anti-VLA4/VCAM-1-induced mobilization requires cooperative signaling through the kit/mkit ligand pathway. Blood 1998;91:2231-2239 (Pubitemid 28155495)
25. Papayannopoulou T, Craddock C, Nakamoto B, et al. The VLA4/VCAM-1 adhesion pathway defines contrasting mechanisms of lodgement of transplanted murine hemopoietic progenitors between bone marrow and spleen. Proc Natl Acad Sci USA 1995;92:9647-9651
26. Faull RJ, Ginsberg MH. Dynamic regulation of integrins. Stem Cells 1995;13:38-46
27. Shattil SJ, Kashiwagi H, Pampori N. Integrin signaling: the platelet paradigm. Blood 1998;91:2645-2657
28. Huttenlocher A, Ginsberg MH, Horwitz AF. Modulation of cell migration by integrin-mediated cytoskeletal linkages and ligand-binding affinity. J Cell Biol 1996;134:1551-1562 (Pubitemid 26318026)
29. Martin-Bermudo MD, Dunin-Borkowski OM, Brown NH. Modulation of integrin activity is vital for morphogenesis. J Cell Biol 1998;141:1073-1081 (Pubitemid 28243973)
30. + hematopoietic progenitor cells in humans. Blood 2008;111:3893-3895 • This paper reports data demonstrating the mobilizing effect of natalizumab in humans.
31. Bonig H, Wundes A, Chang KH, et al. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 2008;111:3439-3441 • This paper includes data demonstrating the mobilizing effect of natalizumab in humans.
32. Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008;14:1045-1056
33. Bruns I, Steidl U, Kronenwett R, et al. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion 2006;46:180-185 (Pubitemid 43381751)
34. Kroschinsky F, Hölig K, Platzbecker U, et al. Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma. Transfusion 2006;46:1417-1423 (Pubitemid 44117972)
35. + cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008;41:331-338
36. Cashen A, Lopez S, Gao F, et al. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant 2008;14:1253-1261
37. Devine SM, Flomenberg N, Vesole DH, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004;22:1095-1102 (Pubitemid 41095043)
38. Flomenberg N, Devine SM, Dipersio JF, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005;106:1867-1874 (Pubitemid 41208607)
39. Podolsky DK. Selective adhesion-molecule therapy and inflammatory bowel disease - a tale of Janus? N Engl J Med 2005;353:1965-1968
40. Hauser SL, Weiner HL. Natalizumab: immune effects and implications for therapy. Ann Neurol 2006;59:731-732 (Pubitemid 43673148)
41. Ropper AH. Selective treatment of multiple sclerosis. N Engl J Med 2006;354:965-967
42. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910 (Pubitemid 43313657)
43. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-923 (Pubitemid 43313658)
44. Hesterberg PE, Winsor-Hines D, Briskin MJ, et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology 1996;111:1373-1380 (Pubitemid 26362264)
45. Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn's disease. Gastroenterology 2001;121:268-274 (Pubitemid 32729374)
46. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32
47. Elices MJ. Natalizumab. Elan/Biogen. Curr Opin Investig Drugs 2003;4:1354-1362
48. Ropper AH. Selective treatment of multiple sclerosis. N Engl J Med 2006;354:965-7
49. Available from: http://investor.biogenidec. com/phoenix.zhtml?c=148682 & p=irol-TPME
50. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-368 (Pubitemid 41132340)
51. Kleinschmidt-Demasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369-374 (Pubitemid 41132341)
52. Krumbholz M, Meinl I, Kümpfel T, et al. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 2008;71:1350-1354
53. Khatri BO, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 2009;72:402-409
54. Stuve O, Marra CM, Cravens PD, et al. Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch Neurol 2007;64:169-176 (Pubitemid 46256555)
55. Phillips JT, O'Connor PW, Havrdova E, et al. Infusion-related hypersensitivity reactions during natalizumab treatment. Neurology 2006;67:1717-1718 (Pubitemid 44747962)
56. Ghosh S, Goldin E, Gordon FH. Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32
57. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23 (Pubitemid 36026342)
58. Christ O, Kronenwett R, Haas R, et al. Exp Hematol 2001;29:380-390
59. Becker PS, Appelbaum FR, Chien S. Oral small molecule inhibitor of VLA-4 overcomes adhesion mediated chemotherapy resistance of acute myeloid leukemia (AML) blasts in vitro, without impairment of normal blood cell recovery when combined with chemotherapy in vivo. Oral Presentation 858, San Francisco: Annual Meeting of the American Society of Hematology, 2008 [abstract 858]. Blood (ASH Annual Meeting Abstracts) 2008;112
60. Matsunaga T, Fukai F, Miura S, et al. Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia. Leukemia 2008;22:353-60 This paper describes VLA 4-mediated therapy of leukemia. (Pubitemid 351250540)
61. Becker PS, Kopecky KJ, Wilks AN, et al. Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia. Blood 2009;113:866-874
62. Noborio-Hatano K, Kikuchi J, Takatoku M, et al. Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene 2009;28:231-242
63. Rose DM. The role of the α4 integrin-paxillin interaction in regulating leukocyte trafficking. Exp Mol Med 2006;38:191-195 (Pubitemid 44033230)
64. Bonig H, Watts KL, Chang KH, et al. Concurrent blockade of α4-integrin and CXCR4 in hematopoietic stem/progenitor cell mobilization. Stem Cells 2009;27:836-837